A complement C8 test evaluates the activity of complement component 8, a three-chain protein that penetrates a target membrane during formation of the membrane attack complex. Inherited C8 deficiency can interrupt terminal complement killing while leaving many other immune functions intact. The characteristic consequence is an increased risk of invasive or recurrent Neisseria infection, particularly meningococcal meningitis or bloodstream infection. Some people are not diagnosed until adolescence or adulthood because ordinary immune responses remain largely functional.
C8 testing is normally performed only after pathway screening points to a shared terminal defect. Both CH50 and AH50 are usually absent in complete deficiency, while C3 and C4 concentrations can remain normal. A low functional result still requires confirmation because acute consumption, advanced liver disease, protein loss, complement-blocking treatment, and specimen degradation can imitate deficiency. This article explains C8’s unusual alpha-beta-gamma structure, how the test is interpreted, how genetic subtypes differ, and what prevention and emergency plans follow a confirmed diagnosis.
- C8 contains alpha, beta, and gamma chains and creates the first major membrane lesion in the terminal complement complex.
- C8 deficiency may involve the linked alpha-gamma subunit or the beta subunit, depending on the affected gene.
- Complete deficiency usually produces absent CH50 and AH50 with normal upstream complement concentrations.
- Recurrent meningococcal disease is the most important clinical trigger for testing.
- MenACWY and MenB vaccination, boosters, infection education, and sometimes antibiotics remain necessary after diagnosis.
Table of Contents
- Why C8 is different from other terminal components
- The pathway pattern that leads to C8 testing
- Reading a C8 functional test result
- C8 alpha-gamma and C8 beta deficiency
- What the infection history may look like
- Consumption, treatment, and false-low results
- Confirming the diagnosis and evaluating relatives
- Reducing infection risk and responding to symptoms
Why C8 is different from other terminal components
After the three complement activation pathways converge, a C5 convertase cleaves C5. C5b binds C6 and C7, allowing the complex to associate with a target membrane. C8 then binds C5b-7 and performs a decisive mechanical step: parts of C8 insert into the lipid bilayer and create a small membrane lesion. C9 molecules subsequently gather around this scaffold and polymerize into a larger pore.
C8 is structurally unusual because it is a heterotrimer composed of three distinct chains. The alpha and gamma chains are linked together as one subunit, while the beta chain associates noncovalently with them. The corresponding genes are C8A, C8G, and C8B. C8 alpha contains a membrane-attack complex/perforin-like domain that contributes directly to membrane penetration. C8 beta helps the complex attach properly to C5b-7. The smaller gamma chain is linked to alpha and has regulatory and structural roles that are still being clarified.
This architecture creates more than one inherited deficiency pattern. A defect affecting C8A usually causes loss of the alpha-gamma subunit because the two travel together. A defect in C8B causes beta-chain deficiency. In either case, complete terminal lytic activity is markedly impaired, but an antigen assay directed at only one chain may not tell the whole story. Functional testing asks whether the assembled C8 complex works, regardless of which chain is abnormal.
Upstream complement functions remain available in C8 deficiency. C3 can be cleaved, C3b can opsonize bacteria, and C5a can recruit inflammatory cells. The missing step is efficient membrane attack complex formation. This helps explain why patients can make vaccine antibodies and may not have constant infections, yet remain specifically vulnerable to Neisseria.
C8 deficiency should not be confused with excessive C8 or soluble C5b-9 deposition in inflammatory disease. Routine C8 functional testing is intended to detect inadequate terminal function. It does not measure the intensity of complement activation in a kidney biopsy, transplant, or thrombotic microangiopathy.
The pathway pattern that leads to C8 testing
The laboratory investigation generally starts with two functional screens rather than an isolated C8 order.
The CH50 test requires the classical pathway and all shared terminal components. The AH50 test requires the alternative pathway and the same terminal sequence. Complete C8 deficiency interrupts both, so both values are usually extremely low or undetectable.
Paired screening creates a practical map:
| CH50 | AH50 | Initial localization |
|---|---|---|
| Low or absent | Normal | Early classical component, such as C1, C2, or C4 |
| Normal | Low or absent | Alternative-pathway factor or regulator |
| Low or absent | Low or absent | C3 or C5-C9 defect, severe consumption, drug effect, or specimen problem |
| Normal | Normal | Complete C8 deficiency is unlikely |
The next comparison is with C3 and C4 concentrations. Normal C3 and C4 support an isolated late-component defect. Low values make widespread complement consumption, reduced synthesis, or protein loss more plausible.
Clinical history determines how aggressively to continue. Recurrent invasive meningococcal disease is a strong indication. Testing may also follow one episode when it occurs at an unusual age or with an uncommon serogroup, when prior “aseptic” or culture-negative meningitis could have been bacterial, or when close relatives have similar infections. Disseminated gonococcal infection is another clue.
C8 testing is not a routine response to repeated viral upper-respiratory infections. It is also not the appropriate first test for low immunoglobulins, chronic sinusitis with poor vaccine responses, or isolated angioedema. Those patterns involve different branches of immune evaluation.
Because acute meningococcal disease itself activates complement, a screen drawn during sepsis can be abnormal from consumption. Clinicians may test during hospitalization to identify a major defect quickly, then repeat the studies after recovery. Public-health vaccination and education do not need to wait for final genetic proof when the suspicion is high.
Reading a C8 functional test result
A C8 functional assay determines whether C8 in the patient’s serum can restore lytic activity to a C8-deficient test system. The result may be reported in units per milliliter or as percent activity. One current reference laboratory uses a threshold of at least 57 U/mL. That value is method-specific and should not be applied to results from another laboratory.
A very low value means the serum did not supply normal C8 activity. It does not immediately reveal why. The possibilities include:
- Complete absence of one C8 subunit.
- A nonfunctional C8 protein that remains antigenically detectable.
- Partial deficiency with residual activity.
- Consumption during systemic complement activation.
- Inhibition by a medicine or acquired factor.
- Loss of activity from improper specimen handling.
Functional testing is particularly useful for C8 because the protein has multiple chains. An immunochemical assay might measure beta chain despite an alpha-gamma defect, or vice versa, depending on the antibody used. A whole-C8 functional assay detects failure of the complete complex.
Specimen handling can be the deciding issue. Complement function is heat-labile. Serum generally needs prompt separation and freezing according to the performing laboratory’s instructions. Warm shipping, delayed centrifugation, or repeated thawing can make an otherwise normal sample appear deficient. When C8 is low but the clinical history and other components do not fit, repeat collection is more informative than immediate genetic labeling.
A borderline result deserves restraint. Assay imprecision near a cutoff, carrier status, partial degradation, and residual-function variants can overlap. Complete deficiency usually produces a strikingly abnormal pathway pattern. A slightly low C8 with normal CH50 and AH50 does not fit complete terminal failure and may not carry the same infection risk.
A normal C8 result means that C8 protein quantity and activity were adequate in that assay. If CH50 and AH50 remain absent, the laboratory must investigate C3, C5, C6, C7, or C9, as well as treatment effects. The screens cannot identify C8 specifically because every shared terminal component is required.
C8 alpha-gamma and C8 beta deficiency
Inherited C8 deficiency is most often autosomal recessive. The molecular subtype depends on which chain is affected.
C8 alpha-gamma deficiency
The alpha and gamma chains are encoded by neighboring genes and exist as a linked subunit in the circulating complex. Pathogenic variants in C8A are a recognized cause of alpha-gamma deficiency; variants affecting C8G are much less commonly implicated. When the alpha-gamma subunit is absent, C8 cannot penetrate membranes normally.
C8 alpha-gamma deficiency has been described in multiple populations and may be relatively more represented in some African and Asian ancestry groups. This is a population observation, not a diagnostic rule. People from any ancestry can carry rare C8A variants, and functional testing should drive the workup.
C8 beta deficiency
Pathogenic variants in C8B cause loss or dysfunction of the beta chain. C8 beta is necessary for proper association of C8 with the C5b-7 complex. Some founder variants have been reported more frequently in particular European populations, but comprehensive genetic testing may be needed because not all families carry the common change.
Partial and dysfunctional states
Not every variant produces complete absence. Some individuals have reduced C8 activity, detectable subunits, or dysfunctional complexes. The relationship between residual assay activity and infection risk is not perfectly defined. A person with a convincing neisserial history and reproducible low function deserves specialist assessment even when activity is not zero.
Genetic testing should ideally include sequencing and copy-number analysis of relevant C8 genes when functional studies localize the defect. A variant of uncertain significance does not confirm disease. The laboratory should correlate it with C8 function, pathway results, segregation in relatives, and published or experimental evidence.
The molecular subtype usually does not change the core prevention strategy. Both alpha-gamma and beta deficiency impair membrane attack complex formation and increase neisserial risk. Genetic detail is most useful for confirming inheritance and testing relatives accurately.
What the infection history may look like
The hallmark is invasive meningococcal disease, but the history can be less obvious than repeated culture-proven meningitis.
One person may have meningococcal sepsis in childhood and a second episode in adulthood. Another may recall two hospitalizations labeled “bacterial meningitis,” with the organism documented only once. Some patients are diagnosed after several siblings become ill. Others remain well until a high-exposure setting, such as communal housing, military service, or travel, increases contact with meningococcal strains.
Terminal complement deficiency can predispose to meningococcal serogroups that cause relatively little disease in the general population. Historical studies have also described recurrent disease with variable severity. Preserved opsonization and antibody responses may moderate some episodes, but severe shock, neurologic injury, hearing loss, limb ischemia, and death remain possible. No episode should be considered “mild” in advance.
Meningococcal meningitis may cause sudden fever, severe headache, neck stiffness, vomiting, light sensitivity, altered mental state, or seizures. Meningococcemia may present with profound malaise, limb or muscle pain, rapid breathing, cold extremities, hypotension, and petechial or purpuric skin lesions. A rash can appear late or not at all.
Disseminated gonococcal infection can produce a triad of skin lesions, tendon-sheath inflammation, and migratory joint pain, or it can cause septic arthritis. Mucosal symptoms may be absent. Recurrent dissemination should prompt complement testing, but sexual-health testing and partner treatment remain essential.
C8 deficiency does not generally cause low total immunoglobulins or poor lymphocyte numbers. A person with chronic ear, sinus, and lung infections may have a different or additional immune problem. An immunologist reviews organism type, infection site, age at onset, vaccine response, anatomy, and medication rather than assuming one diagnosis explains every illness.
Family history may contain sudden infection deaths or meningitis without a named organism. Because autosomal recessive conditions can skip generations and affected siblings can have different exposure histories, the absence of disease in parents is expected and does not argue against C8 deficiency.
Consumption, treatment, and false-low results
Several acquired situations can lower C8 function or make pathway testing appear terminally deficient.
Systemic complement consumption
Severe sepsis, immune-complex disease, vasculitis, and complement-mediated blood or kidney disorders can activate the cascade extensively. When C8 is consumed along with upstream components, C3 and C4 may also fall. A return to normal after recovery supports acquired consumption.
Liver dysfunction and protein loss
Most circulating complement proteins are synthesized largely in the liver. Advanced liver failure can reduce several components. Nephrotic syndrome, protein-losing enteropathy, major burns, plasma exchange, and massive dilution can lower serum proteins broadly. Albumin, total protein, urine protein, coagulation tests, and the rest of the complement profile help distinguish these mechanisms.
Complement-targeted medicines
C5 inhibitors prevent C5b formation, so the cascade never reaches C8. CH50 and AH50 may be absent even though C8 itself is normal. Drugs acting at C3 or other upstream steps have similar consequences. Component-specific assays can be affected differently depending on their design. Medication name, dose, last administration, and therapeutic target must accompany the sample.
Improper handling
Functional complement testing requires intact proteins. Delayed processing or thawing can reduce activity. A pattern in which many functional components are low but antigen concentrations and clinical findings are normal strongly suggests a preanalytical problem.
Acute age-related considerations
Newborn complement activity is lower than adult activity. Pediatric results should use age-appropriate interpretation, particularly in premature or critically ill infants. A genuine invasive meningococcal infection still warrants evaluation, but an adult cutoff should not be imposed without laboratory guidance.
| C8-related pattern | Interpretation to prioritize |
|---|---|
| Absent C8 function, absent CH50/AH50, normal C3/C4, no inhibitor drug | Inherited C8 deficiency |
| Low C8 plus low C3/C4 during severe infection | Complement consumption |
| Absent CH50/AH50 during eculizumab or another C5 blocker | Expected pharmacologic blockade |
| Low C8 from one delayed sample, normal repeat | Specimen degradation |
| Multiple low proteins with severe liver failure or protein loss | Acquired low production or loss |
| Borderline C8 but normal pathway screens | Complete deficiency unlikely; interpret cautiously |
Confirming the diagnosis and evaluating relatives
Confirmation should proceed in a sequence that separates pathway failure, component identity, and inheritance.
First, repeat CH50 and AH50 under correct handling conditions. Confirm the absence of complement inhibitors and note whether testing occurred during acute illness. Persistent dual absence is the foundation of the workup.
Second, assess C3 and C4 concentrations. Preserved upstream proteins support a terminal defect. If both are low, repeat after recovery and investigate consumption, liver disease, or protein loss.
Third, perform functional tests for C5 through C9 or use laboratory reconstitution studies. If addition of normal C8 restores lysis while other components do not, the defect localizes to C8. Where available, subunit-specific antigen studies can distinguish alpha-gamma from beta deficiency.
Fourth, obtain genetic confirmation. The test should match the functional suspicion and include relevant C8 genes. Genetics can establish the subtype, confirm recessive inheritance, and enable targeted family testing. Results should be reviewed with an immunologist or genetic counselor.
Fifth, assess relatives. Full siblings of an affected person may have inherited both familial variants even if they have never been infected. Testing them before their first exposure-related illness can be lifesaving. Parents and children are often carriers unless the other parent also carries a pathogenic variant. The family’s exact variants determine who needs testing.
Sixth, document the diagnosis in language that changes care: “complete terminal complement C8 deficiency” is more useful than “low complement.” Include the genetic subtype if known, the vaccine plan, antibiotic instructions, and emergency precautions.
Once complete deficiency is confirmed, frequent repeat C8 measurements are not generally useful. The enduring priorities are prevention and early treatment. Rechecking may be appropriate if the initial diagnosis remains uncertain or if a partial functional defect is being characterized.
Reducing infection risk and responding to symptoms
Risk reduction requires several layers because no single intervention fully compensates for the absent membrane attack complex.
Meningococcal vaccination: People with persistent complement component deficiency need both MenACWY and MenB protection under a high-risk schedule. Primary-series dose numbers vary by age and product. Boosters continue for as long as the risk remains. Current U.S. guidance includes repeated MenACWY boosters and MenB boosters after the primary series; clinicians should consult the current schedule because products and intervals change. A pentavalent MenABCWY option may be used in eligible people when both components are indicated at the same visit.
Vaccination limits: Vaccine-generated antibodies still depend partly on complement for optimal bactericidal action. Breakthrough infection can occur, and some meningococci are not covered by the vaccine antigens. Patients must not use vaccination status as a reason to delay care.
Antibiotic prevention: Depending on age, prior invasive disease, local practice, access to emergency services, and resistance patterns, a specialist may recommend daily prophylaxis or an emergency supply. Instructions should specify exactly when to take a dose and emphasize simultaneous urgent medical assessment.
Medical identification: Carry a card or digital alert stating “C8 terminal complement deficiency—high risk for invasive meningococcal disease.” Include allergies, prophylactic antibiotic, vaccine dates, and specialist contacts. Tell new clinicians, dentists, travel clinics, and emergency teams.
Travel and community exposure: Review destination-specific meningococcal recommendations before travel. Communal living does not need to be avoided, but vaccination status and emergency access should be current. During a public-health outbreak, additional measures may be recommended.
Sexual health: Prompt testing and treatment for gonorrhea reduces the chance of dissemination and transmission. Partners require evaluation according to public-health guidance. Fever, rash, or joint symptoms after exposure need urgent clinical assessment.
Emergency symptoms include fever with severe headache, stiff neck, confusion, unusual drowsiness, vomiting, rapid breathing, severe muscle or limb pain, cold extremities, low-blood-pressure symptoms, or a non-blanching purple rash. Seek emergency care immediately, even when symptoms seem early and even after full vaccination. Tell clinicians about C8 deficiency at the first contact.
A C8 test earns its value when it converts a hidden susceptibility into prevention. Functional confirmation, precise genetic characterization, vaccination, antibiotic planning, and rapid response can substantially reduce the likelihood that the next exposure becomes another invasive infection.
After any breakthrough infection, the prevention plan should be reviewed rather than assuming vaccination “failed” in a simple way. Clinicians may reassess vaccine dates, bacterial serogroup, antimicrobial susceptibility, adherence to prophylaxis, and whether household contacts received public-health treatment. The episode should also be reported clearly in the medical record so future emergency teams recognize the persistent risk.
References
- C8 Complement, Functional, Serum. 2026. Laboratory test guidance.
- Complement deficiencies and infections. 2026. Review article.
- Risk-based Indications for Meningococcal Vaccination. 2026. U.S. Centers for Disease Control and Prevention guidance.
- Factors associated with recurrent meningococcal disease. 2024. NICE evidence review.
- Immunodeficiency: Complement disorders. 2024. Clinical review.
- Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: evidence for the importance of an early diagnosis. 2016. Family case series with genetic analysis.
Disclaimer
This article is for general education and does not replace individualized immunology, infectious-disease, vaccination, or genetic advice. C8 functional results can be distorted by acute consumption, complement-inhibiting medicines, and specimen handling and require confirmation within a full pathway evaluation. Anyone with suspected meningococcal disease and known or possible terminal complement deficiency needs immediate emergency care, even after vaccination.
